Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30688
Title: A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery.
Austin Authors: Coulson, Tim G ;Miles, Lachlan F ;Serpa Neto, Ary ;Pilcher, D;Weinberg, Laurence ;Landoni, G;Zarbock, A;Bellomo, Rinaldo 
Affiliation: Intensive Care
Department of Anaesthesiology and Peri-Operative Medicine, Monash University and Alfred Health, Melbourne, Australia..
Anaesthesia
Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), Monash University, Melbourne, Australia..
Department of Intensive Care, Alfred Health, Melbourne, Australia..
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy..
Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Germany..
Issue Date: Sep-2022
Publication information: Anaesthesia 2022; 77(9): 999-1009
Abstract: Acute kidney injury is common after cardiac surgery. Vasoplegic hypotension may contribute to kidney injury, and different vasopressors may have variable effects on kidney function. We conducted a double-blind, randomised feasibility trial comparing peri-operative angiotensin-2 with noradrenaline. We randomly allocated 60 patients at two centres to a blinded equipotent angiotensin-2 or noradrenaline infusion intra-operatively and for up to 48 h postoperatively, titrated to mean arterial pressure of 70-80 mmHg. Primary feasibility outcomes included consent rate, protocol adherence, infusion duration, mean arterial pressure maintenance in the target range and major adverse outcomes. Secondary outcomes included kidney injury rate. The consent rate was 47%. Protocol adherence was 100% in the angiotensin-2 group and 94% in the noradrenaline group. Study drug duration was median (IQR [range]) 217 (160-270 [30-315]) vs. 185 (135-301 [0-480]) min (p = 0.78) min intra-operatively, and 5 (0-16 [0-48]) vs. 14.5 (4.8-29 [0-48]) hours (p = 0.075) postoperatively for angiotensin-2 and noradrenaline, respectively. The mean arterial pressure target was achieved postoperatively in 25 of 28 (89%) of the angiotensin-2 group and 27 of 32 (84%) of the noradrenaline group. One participant had a stroke, one required extracorporeal support and three required renal replacement therapy, all in the noradrenaline group (p = 0.99, p = 0.99 and p = 0.1). Acute kidney injury occurred in 7 of 28 in the angiotensin-2 group vs. 12 of 32 patients in the noradrenaline group (p = 0.31). This pilot study suggests that a trial comparing angiotensin-2 with noradrenaline is feasible. Its findings justify further investigations of angiotensin-2 in cardiac surgery.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30688
DOI: 10.1111/anae.15802
ORCID: 0000-0003-1520-9387
0000-0003-2044-5560
0000-0001-7403-7680
0000-0002-1650-8939
PubMed URL: 35915923
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35915923/
Type: Journal Article
Subjects: angiotensin-2
cardiac surgery
kidney injury
noradrenaline
norepinephrine
randomised controlled trial
renal dysfunction
renal failure
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.